about
CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse modelRole of metallothioneins in benign and malignant thyroid lesionsHobnail variant of papillary thyroid carcinoma: molecular profiling and comparison to classical papillary thyroid carcinoma, poorly differentiated thyroid carcinoma and anaplastic thyroid carcinomaTSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasiaNew insights into the diagnosis of nodular goiter.Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's ThyroiditisBRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinomaIs follow-up BRAF(V600E) mutation analysis helpful in the differential diagnosis of thyroid nodules with negative results on initial analysis?Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.BRAF(V600E) Mutation, RET/PTC1 and PAX8-PPAR Gamma Rearrangements in Follicular Epithelium Derived Thyroid Lesions - Institutional Experience and Literature ReviewDiagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese PatientsNovel and Practical Scoring Systems for the Diagnosis of Thyroid NodulesHerpes and polyoma family viruses in thyroid cancer.Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery CentersPatterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathologyComprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer.Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain.BRAF mutation testing in clinical practice.Genetics and epigenetics of sporadic thyroid cancer.Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology.Activating BRAF Mutations Detected in Mixed Hürthle Cell Carcinoma and Multifocal Papillary Carcinoma of the Thyroid Gland: Report of an Unusual Case and Review of the Literature.Expression of Hypoxia-Associated Protein HIF-1α in Follicular Thyroid Cancer is Associated with Distant Metastasis.MicroRNAs in the thyroid.Values of molecular markers in the differential diagnosis of thyroid abnormalities.Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.Thyroid FNAC containing hürthle cells and hürthle-like cells: A study of 128 casesAssessment of cellularity, genomic DNA yields, and technical platforms for BRAF mutational testing in thyroid fine-needle aspirate samples.Subclassification of "atypia of undetermined significance" in thyroid fine-needle aspirates.Lack of mutational events of RAS genes in sporadic thyroid cancer but high risk associated with HRAS T81C single nucleotide polymorphism (case-control study).Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing.Recent advances in the surgical treatment of differentiated thyroid cancer: a comprehensive review.INAVA promotes aggressiveness of papillary thyroid cancer by upregulating MMP9 expression.Utility of molecular testing in the management of thyroid nodules - a clinical perspective.Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
P2860
Q28271131-D84BA8F8-D1B2-4D35-AE4C-DC97C5AE3A43Q28393061-1BE43C6E-F5D6-45DA-9A42-77413C1D82ECQ33591794-94F071CE-AF31-41AD-9866-E8B68026F1C4Q33636784-CFBF9749-746D-4C6B-9AA9-B3A948EB8C56Q33827492-58D7FAF2-590C-437E-A57E-0F9A38305533Q33884794-BE065C3F-E21A-4F56-91B9-CD3C5E725664Q34103836-804F03CB-CDE1-464F-B98A-ABAB5A37F4FFQ34282488-3531B330-3092-4FC1-8053-0C8BA1641B4FQ34625948-516BF0A6-4B0E-4191-96D1-0E5621AD486DQ35345217-0BE2C7C9-F18A-428C-8CEE-FC66F7B16CE1Q35609167-068921CA-A749-405C-A1F4-B2795B103C6FQ35690041-09036C1C-9D72-44C6-A142-3647D1A5489AQ35932262-92C47C36-5C0E-4706-ACDB-7CE9697C6881Q36139842-ABE28E5B-5B9B-43B7-8A13-E2F7EF0C183BQ36640448-561FC276-2412-4C9E-911A-0742A3335CD9Q36786213-4FEDF5C9-480A-4F59-B217-BC54C92BAFD4Q36991284-4DD27DF6-26E9-43F1-8879-262B54786D4FQ37086149-6173758B-4FF1-4769-A725-F2597838C04DQ37293498-83BA3685-F42F-4A81-B2EB-060897EF7699Q37720167-ECC2E074-6ABF-468C-8331-7AA7D54A64FBQ37954574-F442268D-A8BB-4876-B098-C6D04161951BQ37988572-5761BB72-F5F5-4247-B308-DB86C98D4F63Q38128097-81581073-1897-45FC-90C9-A9554E217D1DQ38182019-C8A707C4-F7C4-4D8D-8BC1-A34859C59DB8Q38785849-DB4787A9-9234-446C-AFB9-45E298309363Q38802912-1D97D8C3-FF24-4B16-80DB-40A570918B3CQ39030847-C3EBF092-C82B-4DA0-B12A-11C25C9859EFQ39051174-1A771A80-A511-477C-A1E8-05145F2E7000Q40629784-C34934E4-B9C8-4227-B1E9-3E550CC51D33Q40844396-D4EA840B-5D70-4596-A5CD-6978C5CC5B8AQ42229477-6DCA024B-9F8D-4841-A45B-878B595466A9Q44297101-44FC647B-DD5B-454C-B784-7246AF850829Q44481173-A3CC4456-11A8-46FC-A29C-3D70FD48CCBFQ45106309-51F25532-BA22-4B46-96A0-7D71A06866ACQ50922815-D09FA3D8-7BFF-43BD-9BC1-29D97440AAFFQ51272259-FC6F1CE6-35A8-4F86-AD36-873AFBA93BDBQ52597586-0FE2C219-6A35-4CA3-9460-53A3851E8A1BQ53334940-B2892A7D-6811-43B5-BF31-6ED291A153B0Q54339901-E03BA041-1809-43AC-9C1E-19495F2B5158Q54373420-9E6B20BD-2E76-40B0-9E03-D4CE5861C9B9
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular analysis of thyroid tumors.
@en
Molecular analysis of thyroid tumors.
@nl
type
label
Molecular analysis of thyroid tumors.
@en
Molecular analysis of thyroid tumors.
@nl
prefLabel
Molecular analysis of thyroid tumors.
@en
Molecular analysis of thyroid tumors.
@nl
P1433
P1476
Molecular analysis of thyroid tumors.
@en
P2093
Yuri E Nikiforov
P2888
P304
P356
10.1038/MODPATHOL.2010.167
P478
24 Suppl 2
P577
2011-04-01T00:00:00Z
P5875
P6179
1042692394